Mayo Clinic Laboratory and Pathology Research Roundup: May 21

By Kelley Luedke • May 21, 2018

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy

Currently no genomic signature exists to distinguish men most likely to progress on adjuvant androgen deprivation therapy (ADT) after radical prostatectomy (RP) for high risk prostate cancer. Mayo Clinic researchers developed and validated a gene expression signature to predict response to postoperative ADT. A training set consisting of 284 RP patients was established after 1:1 propensity score matching metastasis between adjuvant-ADT(a-ADT) treated and no-ADT treated groups. An ADT Response Signature (ADT-RS) was identified from neuroendocrine and AR-signaling related genes. Two independent cohorts were used to form three separate data sets for validation. The primary endpoint of the analysis was postoperative metastasis. Patients with High ADT-RS benefited from a-ADT. In combination with prognostic risk factors, use of ADT-RS may thus allow for identification of ADT-responsive tumors that may benefit most from early androgen blockade after RP. The study was published in Clinical Cancer Research.

Published to PubMed This Week

• • • • • PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness
          American Journal of Surgical Pathology
        • Privacy-Preserving Predictive Modeling: Harmonization of Contextual Embeddings From Different Sources
          JMIR Medical Informatics
        • in vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam Against Resistant Gram-Negative Bacilli
          Antimicrobial Agents and Chemotherapy
        • Elevated LGI1-IgG CSF Index Predicts Worse Neurological Outcome
          Annals of Clinical and Translational Neurology
        • Spindle Cell Rhabdomyosarcoma of Bone with FUS-TFCP2 Fusion: Confirmation of a Very Recently Described Rhabdomyosarcoma Subtype
          Histopathology
        • Classification of Breast Masses Using a Computer-Aided Diagnosis Scheme of Contrast Enhanced Digital Mammograms
          Annals of Biomedical Engineering
        • Ewing Sarcoma of the Head and Neck: The Mayo Clinic Experience
          Head Neck
        • BAP1 Loss is Unusual in Well-Differentiated Papillary Mesothelioma and May Predict Development of Malignant Mesothelioma
          Human Pathology

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.